-
Je něco špatně v tomto záznamu ?
Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
K. Kalwak, M. Mielcarek, K. Patrick, J. Styczynski, P. Bader, S. Corbacioglu, B. Burkhardt, KW. Sykora, K. Drabko, J. Gozdzik, F. Fagioli, J. Greil, B. Gruhn, R. Beier, F. Locatelli, I. Müller, PG. Schlegel, P. Sedlacek, KD. Stachel, C....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 1997-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- busulfan analogy a deriváty MeSH
- dítě MeSH
- hematologické nádory * terapie MeSH
- lidé MeSH
- nemoc štěpu proti hostiteli * MeSH
- příprava pacienta k transplantaci * MeSH
- thiotepa MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- vidarabin analogy a deriváty MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Treosulfan-based conditioning prior to allogeneic transplantation has been shown to have myeloablative, immunosuppressive, and antineoplastic effects associated with reduced non-relapse mortality (NRM) in adults. Therefore, we prospectively evaluated the safety and efficacy of treosulfan-based conditioning in children with hematological malignancies in this phase II trial. Overall, 65 children with acute lymphoblastic leukemia (35.4%), acute myeloid leukemia (44.6%), myelodysplastic syndrome (15.4%), or juvenile myelomonocytic leukemia (4.6%) received treosulfan intravenously at a dose of 10 mg/m2/day (7.7%), 12 g/m2/day (35.4%), or 14 g/m2/day (56.9%) according to their individual body surface area in combination with fludarabine and thiotepa. The incidence of complete donor chimerism at day +28 was 98.4% with no primary and only one secondary graft failure. At 36 months, NRM was only 3.1%, while relapse incidence was 21.7%, and overall survival was 83.0%. The cumulative incidence of acute graft-vs.-host disease was 45.3% for grades I-IV and 26.6% for grades II-IV. At 36 months, 25.8% overall and 19.4% moderate/severe chronic graft-vs.-host disease were reported. These data confirm the safe and effective use of treosulfan-based conditioning in pediatric patients with hematological malignancies. Therefore, treosulfan/fludarabine/thiotepa can be recommended for myeloablative conditioning in children with hematological malignancies.
Children's Hospital Regina Margherita University of Turin Turin Italy
Children's Hospital University of Erlangen Erlangen Germany
Department of Pediatric Hematology and Oncology Collegium Medicum UMK Torun Bydgoszcz Poland
Department of Pediatric Hematology and Oncology University Hospital Motol Prague Czech Republic
Department of Pediatric Hematology Oncology and BMT University Hospital Muenster Muenster Germany
Department of Pediatrics Hannover Medical School Hannover Germany
Department of Pediatrics Jena University Hospital Jena Germany
Depertment of Pediatrics 3 University Hospital of Essen Essen Germany
Great Ormond Street Hospital London UK
IRCCS Bambino Gesú Children's Hospital Sapienza University of Rome Rome Italy
Medical College University Children's Hospital in Cracow Jagiellonian University Cracow Poland
Sheffield Children's Hospital Sheffield UK
University Children's Hospital Heidelberg Heidelberg Germany
University Children's Hospital of Wuerzburg Wuerzburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020022
- 003
- CZ-PrNML
- 005
- 20210830101627.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-020-0869-6 $2 doi
- 035 __
- $a (PubMed)32203268
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kalwak, Krzysztof $u Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. krzysztof.kalwak@gmail.com
- 245 10
- $a Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies / $c K. Kalwak, M. Mielcarek, K. Patrick, J. Styczynski, P. Bader, S. Corbacioglu, B. Burkhardt, KW. Sykora, K. Drabko, J. Gozdzik, F. Fagioli, J. Greil, B. Gruhn, R. Beier, F. Locatelli, I. Müller, PG. Schlegel, P. Sedlacek, KD. Stachel, C. Hemmelmann, AK. Möller, J. Baumgart, A. Vora
- 520 9_
- $a Treosulfan-based conditioning prior to allogeneic transplantation has been shown to have myeloablative, immunosuppressive, and antineoplastic effects associated with reduced non-relapse mortality (NRM) in adults. Therefore, we prospectively evaluated the safety and efficacy of treosulfan-based conditioning in children with hematological malignancies in this phase II trial. Overall, 65 children with acute lymphoblastic leukemia (35.4%), acute myeloid leukemia (44.6%), myelodysplastic syndrome (15.4%), or juvenile myelomonocytic leukemia (4.6%) received treosulfan intravenously at a dose of 10 mg/m2/day (7.7%), 12 g/m2/day (35.4%), or 14 g/m2/day (56.9%) according to their individual body surface area in combination with fludarabine and thiotepa. The incidence of complete donor chimerism at day +28 was 98.4% with no primary and only one secondary graft failure. At 36 months, NRM was only 3.1%, while relapse incidence was 21.7%, and overall survival was 83.0%. The cumulative incidence of acute graft-vs.-host disease was 45.3% for grades I-IV and 26.6% for grades II-IV. At 36 months, 25.8% overall and 19.4% moderate/severe chronic graft-vs.-host disease were reported. These data confirm the safe and effective use of treosulfan-based conditioning in pediatric patients with hematological malignancies. Therefore, treosulfan/fludarabine/thiotepa can be recommended for myeloablative conditioning in children with hematological malignancies.
- 650 _2
- $a busulfan $x analogy a deriváty $7 D002066
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 12
- $a hematologické nádory $x terapie $7 D019337
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a thiotepa $7 D013852
- 650 12
- $a příprava pacienta k transplantaci $7 D019172
- 650 _2
- $a vidarabin $x analogy a deriváty $7 D014740
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mielcarek, Monika $u Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
- 700 1_
- $a Patrick, Katharine $u Sheffield Children's Hospital, Sheffield, UK
- 700 1_
- $a Styczynski, Jan $u Department of Pediatric Hematology and Oncology, Collegium Medicum UMK Torun, Bydgoszcz, Poland
- 700 1_
- $a Bader, Peter $u Department for Children and Adolescents, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe University, Frankfurt, Germany
- 700 1_
- $a Corbacioglu, Selim $u University Hospital of Regensburg, Regensburg, Germany
- 700 1_
- $a Burkhardt, Birgit $u Department of Pediatric Hematology, Oncology and BMT, University Hospital Muenster, Muenster, Germany
- 700 1_
- $a Sykora, Karl Walter $u Department of Pediatrics, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Drabko, Katarzyna $u Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland
- 700 1_
- $a Gozdzik, Jolanta $u Medical College, University Children's Hospital in Cracow Jagiellonian University, Cracow, Poland
- 700 1_
- $a Fagioli, Franca $u Children's Hospital Regina Margherita, University of Turin, Turin, Italy
- 700 1_
- $a Greil, Johann $u University Children's Hospital Heidelberg, Heidelberg, Germany
- 700 1_
- $a Gruhn, Bernd $u Department of Pediatrics, Jena University Hospital, Jena, Germany
- 700 1_
- $a Beier, Rita $u Depertment of Pediatrics III, University Hospital of Essen, Essen, Germany
- 700 1_
- $a Locatelli, Franco $u IRCCS Bambino Gesú Children's Hospital, Sapienza University of Rome, Rome, Italy
- 700 1_
- $a Müller, Ingo $u University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Schlegel, Paul Gerhardt $u University Children's Hospital of Wuerzburg, Wuerzburg, Germany
- 700 1_
- $a Sedlacek, Petr $u Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Stachel, Klaus Daniel $u Children's Hospital, University of Erlangen, Erlangen, Germany
- 700 1_
- $a Hemmelmann, Claudia $u medac GmbH, Wedel, Germany
- 700 1_
- $a Möller, Ann-Kristin $u medac GmbH, Wedel, Germany
- 700 1_
- $a Baumgart, Joachim $u medac GmbH, Wedel, Germany
- 700 1_
- $a Vora, Ajay $u Great Ormond Street Hospital, London, UK
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 55, č. 10 (2020), s. 1996-2007
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32203268 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101627 $b ABA008
- 999 __
- $a ok $b bmc $g 1690752 $s 1140468
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 55 $c 10 $d 1996-2007 $e 20200320 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20210728
